mena-header

MIDDLE EAST & NORTH AFRICA

We supply globally branded pharmaceutical products as well as local brands into multiple territories within MENA. Egypt, Algeria and Saudi Arabia combined contributed approximately 50% to total sales in MENA for the 2017 financial year.

Key Countries

Algeria
Egypt
Morocco
Saudi Arabia
United Arab Emirates

Contribution to Group revenue

mena-contrib

Revenue contribution - by therapeutic category

mena
  • The MENA pharmaceutical sector grew 7,9% and was valued at approximately USD29,3 billion for the year to 30 June 2017.
  • Growth was largely driven by Algeria and Egypt whose value grew in double digits to USD4,8 billion and USD4,6 billion respectively.

Source: June 2017 IMS

STATISTICS

Number of products launched:

Nil

(2016: nil)

IMS value of pipeline as at 30 June 2017 anticipated to be launched in:

0 – 2 years

USD158 million

3 – 5 years

USD9 million

Number of product recalls:

Nil

(2016: nil)

Average staff turnover:

18,7%

(2016: 23,5%)

Number of work-related fatalities:

Nil

(2016: nil)

Number of permanent employees:

mena-employees

Revenue – R’billion 20172016 (CER)*% change
Total 1,10,736
Anaesthetics 0,2>100
Thrombosis 0,20,125
High Potency & Cytotoxics0,30,24
Other Commercial Pharmaceutical Brands0,40,45

* Constant exchange rate: FY16 restated at FY17 average exchange rates. Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture.